Veru (VERU) Retained Earnings (2010 - 2026)
Veru (VERU) posted quarterly Retained Earnings of $367.4 million for Q4 2025, up 221.05% year-over-year from $114.4 million in Q4 2024, and up 7.02% quarter-over-quarter from $343.3 million in Q3 2025.
Veru (VERU) Retained Earnings (2010 - 2026) Analysis & Trends
Veru (VERU) has reported Retained Earnings for 16 consecutive years, with $367.4 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 221.05% year-over-year to $367.4 million; the TTM figure through Dec 2025 stood at $367.4 million (up 221.05% YoY), while the FY2025 annual figure was $343.3 million, up 216.54% from the prior year.
- Retained Earnings grew to $367.4 million in Q4 2025 per VERU's latest filing, from $343.3 million in the prior quarter.
- Across five years, Retained Earnings topped out at $367.4 million in Q4 2025 and bottomed at -$318.7 million in Q2 2025.
- Historically, Retained Earnings has averaged -$54.3 million across 5 years, with a median of -$82.8 million in 2021.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 42389.26% — and 2025, when it plunged 53452.27%.
- Veru's Retained Earnings stood at -$88.2 million in 2021, then slumped by 129.45% to -$202.3 million in 2022, then jumped by 99.71% to -$581519.0 in 2023, then tumbled by 52093.48% to -$303.5 million in 2024, then soared by 221.05% to $367.4 million in 2025.
- Business Quant data shows VERU's Retained Earnings at $367.4 million in Q4 2025, $343.3 million in Q3 2025, and -$318.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Veru | 60.85 Mn | 35.06 Mn | - | 368.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 368.37 Mn |
| Mar 31, 2026 | 367.80 Mn |
| Dec 31, 2025 | 367.40 Mn |
| Sep 30, 2025 | 343.29 Mn |
| Jun 30, 2025 | -318.75 Mn |
| Mar 31, 2025 | -311.42 Mn |
| Dec 31, 2024 | -303.51 Mn |
| Sep 30, 2024 | -294.57 Mn |
| Jun 30, 2024 | 330.56 Mn |
| Mar 31, 2024 | -581,519.00 |
| Dec 31, 2023 | -581,519.00 |
| Sep 30, 2023 | -581,519.00 |
| Jun 30, 2023 | -248.64 Mn |
| Mar 31, 2023 | -236.11 Mn |
| Dec 31, 2022 | -202.32 Mn |
| Sep 30, 2022 | -163.62 Mn |
| Jun 30, 2022 | -124.55 Mn |
| Mar 31, 2022 | 245.92 Mn |
| Dec 31, 2021 | -88.18 Mn |
| Sep 30, 2021 | -2.20 Mn |